Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins

AUTOR(ES)

Tachikawa, Kiyoshi

FONTE

National Academy of Sciences

RESUMO

We describe a facile method to activate or repress transcription of endogenous genes in a quantitative and specific manner by treatment with designed regulatory proteins (DRPs), in which artificial transcription factors (ATFs) are fused to cell-penetrating peptides (CPPs). Penetration of DRPs into cells is mediated by an N-terminal CPP fused to a nuclear localization signal; a DNA-binding domain and a transactivation domain follow. The DNA-binding domain was targeted to the vascular endothelial growth factor (VEGF)-A gene. An agonist DRP was rapidly taken up by cells and transported to the nucleus; soon after, the cells began transcribing the gene and secreting VEGF-A protein in a dose-dependent manner. Multiple copies of a short oligopeptide derived from a minimal transactivation domain of human β-catenin was stronger than VP-16. The SRDX domain from the plant transcription factor, SUPERMAN, changed the DRP to a hypoxia-induced antagonist of VEGF-A. DRPs combine many of the potential benefits of transgenes with those of recombinant proteins.

Documentos Relacionados

• Gene targeting of VEGF-A in thymus epithelium disrupts thymus blood vessel architecture
• VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment
• Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis
• Lymphangioleiomyomatosis—presence of receptor tyrosine kinases and the angiogenesis factor VEGF‐A as potential therapeutic targets
• VEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo